To improve the lives of patients by creating & developing innovative antibody products

Genmab

Approved Partnered Products
Solid Financial Base

DARZALEX® (daratumumab) / DARZALEX *FASPRO*™ (daratumumab & hyaluronidase-fihj)[1], Kesimpta® (ofatumumab)[2], TEPEZZA® (teprotumumab)[3] Arzerra® (ofatumumab)[4]

Our Own Clinical Pipeline
Potential first-in-class / Best-in-class

Tisotumab vedotin[5], epcoritamab[6], DuoBody-PD-L1x4-1BB (GEN1046)[7], DuoBody-CD40x4-1BB (GEN1042)[7], HexaBody®-DR5/DR5, DuoHexaBody®-CD37 (GEN309)[6] & DuoBody®-CD3x5T4 (GEN1044)[6]

Partner-owned Programs in the Clinic
Programs Built on Genmab's Innovation

15 in clinical development with partners with royalty streams for Genmab should they come to market. Includes 7 DuoBody products with Janssen

Technologies & Preclinical
R&D Engine: Powerhouse of Innovation

DuoBody tech., HexaBody tech., DuoHexaBody tech., HexElect® tech. & Rich preclinical pipeline incl. HexaBody-CD38 (GEN3014)[8]

Our Three-pronged Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable & successful biotech

Our Vision

By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

Proprietary technologies allow us to build a world-class pipeline

Match in-house expertise with strategic partnerships → Strong pipeline of first-in-class / best-in-class products

Deep insight into antibody biology & disease targets

2020 Guidance

Income Statement	DKKM	USDM[9]
Revenue	9,250 – 9,850	1,423 – 1,515
Operating expenses	(3,850) – (3,950)	(592) – (608)
Operating income	5,350 – 5,950	823 - 915

[9]USD 1.00 = DKK 6.50

DKK **96B**
~USD 14B[10]
2019 year-end market cap

DKK **2,728M**
~USD 408M[10]
2019 operating expenses
87% invested in R&D

[10]USD 1.00 = DKK 6.6759

DKK **5,366M**
~USD 803M[10]
2019 revenue
77% increase vs 2018

DKK **10,971M**
~USD 1,643M[10]
2019 year end cash position

Revenue
MDDK
(~MUSD[10])



For more information/contact: genmab.com/ir@genmab.com

[1]In dev. by Janssen; [2]In dev. by Novartis; [3]In dev. by Horizon; [4]Commercialized by Novartis, no longer in active clinical development; [5]50:50 w/ Seattle Genetics; [6]50:50 w/ AbbVie; [7]50:50 w/ BioNTech; [8]Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Nov 24, 2020

Innovation Powerhouse

Genmab Proprietary[11] Products

Product	Target	Rights	Indications	Most Advanced Dev. Phase (Pre-clin. / I / I/II / II / III / Appr.)
Tisotumab vedotin	TF	50:50 Genmab Seagen	Cervical cancer	II
			Ovarian cancer	II
			Solid tumors	II
Epcoritamab	CD3, CD20	50:50 Genmab AbbVie	Hem. malig.	I/II
DuoBody-PD-L1x4-1BB	PD-L1, 4-1BB	50:50 Genmab BioNTech	Solid tumors	I/II
DuoBody-CD40x4-1BB	CD40, 4-1BB	50:50 Genmab BioNTech	Solid tumors	I
HexaBody-DR5/DR5	DR5	Genmab	Solid tumors	I
DuoHexaBody-CD37	CD37	50:50 Genmab AbbVie	Hem. malig.	I
DuoBody-CD3x5T4	5T4	50:50 Genmab AbbVie	Solid tumors	I
IND/CTAs in 2020: HexaBody-CD38[12]				Pre-clin.

Products Created by Genmab[13]

Daratumumab	CD38	Janssen[14]	MM	Appr.
			AL Amyloidosis	III
			Non-MM blood cancers	II
Ofatumumab	CD20	Novartis[14,15]	RMS	Appr.
Teprotumumab	IGF-1R	Horizon[14]	TED	Appr.
			dcSSc	I

Partner-owned products incorporating Genmab's Innovation[16]

Amivantamab	EGFR, cMet	Janssen	NSCLC	III
Teclistamab	BCMA, CD3	Janssen	R/R MM	II
Camidanlumab tesirine	CD25	ADC Therapeutics	R/R Hodgkin lymphoma	II
			Solid tumors	I
PRV-015 (AMG 714)	IL-15	Provention Bio	Celiac disease	II
Mim8	FIX(a), FX	Novo Nordisk	Hemophilia A	I/II
Talquetamab	GPRC5D, CD3	Janssen	R/R MM	I
JNJ-63709178	CD123, CD3	Janssen	AML	I
JNJ-63898081	PSMA, CD3	Janssen	Solid tumors	I
JNJ-67571244	CD33, CD3	Janssen	R/R AML; MDS	I
JNJ-70218902	Undisclosed	Janssen	Solid tumors	I
HuMax-IL8	IL8	BMS	Adv. cancers	I
Lu AF82422	alpha-synuclein	Lundbeck	Parkinson's	I
~20 active pre-clinical programs	Partnered & proprietary programs: HuMab, DuoBody, DuoHexaBody and HexaBody			Pre-clin.

Products & Technologies

Tisotumab vedotin
- ADC in development to treat solid tumors
- Very favorable data, Ph 2 cervical cancer
- Ph 2 studies in ovarian & other solid tumors
- 50:50 agreement w/ Seagen

HexaBody-DR5/DR5 (GEN1029)
- Proprietary antibody therapeutic
- Phase 1/2 trial in solid tumors

Epcoritamab (DuoBody-CD3xCD20)
- Bispecific antibody created w/ DuoBody tech
- Phase 1/2 trial in B-cell malignancies
- 50:50 collaboration w/ AbbVie

DuoBody-PD-L1x4-1BB (GEN1046)
- Bispecific antibody created w/ DuoBody tech
- Phase 1/2 trial in solid tumors
- 50:50 agreement w/ BioNTech

DuoBody-CD40x4-1BB (GEN1042)
- Bispecific antibody created w/ DuoBody tech
- Phase 1/2 trial in solid tumors
- 50:50 agreement w/ BioNTech

DuoHexaBody-CD37 (GEN3009)
- Based on combo DuoBody & HexaBody
- FiH trial commenced
- 50:50 collaboration w/ AbbVie

DuoBody-CD3x5T4 (GEN1044)
- Bispecific antibody created w/ DuoBody tech
- FiH trial commenced
- 50:50 collaboration w/ AbbVie

Kesimpta (ofatumumab)
- SubQ formulation approved in US for RMS[14]
- In development by Novartis

DARZALEX (daratumumab) / DARZALEX *FASPRO* (daratumumab & hyaluronidase-fihj)
- First-in-class CD38 antibody
- Approved in certain territories for various multiple myeloma (MM) indications[14]
- First & only SC CD38 antibody approved
- In development by Janssen
- 2019 net sales by Janssen: $2,998M, DKK 3,132M royalties to Genmab

TEPEZZA (teprotumumab)
- Dev. & manufactured by Horizon Therapeutics
- Approved in US for thyroid eye disease[14]
- Created under collaboration with Roche
- Under terms of agreement with Roche, Genmab to receive mid-single digit royalties on sales

DuoBody Platform
- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

HexaBody Platform
- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform
- Antibody technology that combines
- DuoBody & HexaBody platforms
- Creates bispecific antibodies with target-mediated enhanced potency

HexElect Platform
- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting with enhanced selectivity & potency

Founded: 1999
Exchanges: CSE / Nasdaq
Symbol: GMAB
Shares outstanding: 65,545,748
Market Cap as of Nov. 24, 2020:
DKK 145B (~USD 23,076M)

Executive Management:
Jan G. J. van de Winkel, Ph.D. President & CEO
Anthony Pagano, EVP & CFO
Judith Klimovsky M.D., EVP & CDO
Anthony Mancini, EVP & COO

[11]Certain product candidates in development with partners, as noted
[12]Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.
[13]Out-licensed products marketed by partner
[14]See local country prescribing information for precise indications
[15]Also approved as Arzerra for certain CLL indications, not in active clinical development
[16]Products under development by a third-party incorporating Genmab's technology and innovation.